Abstract
#ERSCongress 2025 highlighted key advances in the pathobiology, phenotyping and management of pulmonary vascular diseases, reflecting a shift towards precision medicine in these complex patients https://bit.ly/425cVX6.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureBrandon Budhram, Léon Genecand, Katarina Zeder, Andrea Baccelli, Aleksandar Bokan, Sarah Cullivan, Da‐Hee Park, Vasile Foris, Julien Grynblat, Etienne‐Marie Jutant, Quentin Maloir, Marianne Riou, F. Robert, Andrés Tenes, Simon Valentin, Olivier Sitbon, Athénaïs Boucly
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Predicting mortality with right ventricular function in pulmonary hypertension associated with lung disease
2025
Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis
10.1016/j.jcmg.2020.08.013 · 2021
Clinical relevance of a novel non-invasive surrogate of pulmonary exercise hemodynamics
2025
10.1183/23120541.01135-2025
10.1183/23120541.01135-2025
Impact of comorbidities on therapeutic response in patients with idiopathic pulmonary arterial hypertension
2025
The skeletal muscle index detected by opportunistic chest CT is associated with the long-term adverse prognosis of chronic thromboembolic pulmonary hypertension
2025
10.1183/13993003.01483-2024
10.1183/13993003.01483-2024
StratosPHere 1 study - a novel BMP target engagement biomarker panel for use in clinical trials demonstrates sotatercept alters gene expression in pulmonary arterial hypertension
2025
HS235, a novel activin signaling inhibitor, is highly efficacious in preclinical models of pulmonary hypertension (PH) and heart failure (HF)
2025
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
ALG-801 demonstrates superior therapeutic efficacy in sugen-hypoxia model of pulmonary hypertension
2025
Mechanistic study on luteolin-mediated SIRT1 deacetylation in mitochondrial energy metabolism remodeling in pulmonary arterial hypertension
2025
Integrin α5β1: a promising target for right ventricular dysfunction in pulmonary arterial hypertension
2025
Exploring integrin α5β1 as a potential therapeutic target for pulmonary arterial hypertension: insights from comprehensive multicenter preclinical studies
10.1161/circulationaha.124.070693 · 2025
Rare variants in RYR1/RYR2 associated with CTEPH occurrence: insights from a large whole-genome sequencing analysis
2025
Genetic variants of fibrinogen associated with chronic thromboembolic pulmonary hypertension: insights from the All of Us cohort
2025
10.1056/nejmoa2024277
10.1056/nejmoa2024277
10.1056/nejmoa2213558
10.1056/nejmoa2213558
10.1056/nejmoa2415160
10.1056/nejmoa2415160
10.1056/nejmoa2508170
10.1056/nejmoa2508170
10.1183/13993003.00879-2022
10.1183/13993003.00879-2022
10.1183/13993003.01200-2024
10.1183/13993003.01200-2024
Hemodynamics and phosphodiesterase-5 inhibitor treatment associated with survival in pulmonary hypertension in interstitial lung disease: a PVRI GoDeep meta-registry analysis
10.1164/rccm.202412-2371oc · 2025
Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis
10.1056/nejmoa1811737 · 2018
Association of phosphodiesterase-5 inhibitor treatment with improved survival in pulmonary hypertension associated with COPD in the Pulmonary Vascular Research Institute GoDeep meta-registry
10.1016/j.chest.2024.08.016 · 2025
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
10.1016/s2213-2600(19)30250-4 · 2019
10.7326/0003-4819-158-9-201305070-00003
10.7326/0003-4819-158-9-201305070-00003
10.1056/nejmoa2008470
10.1056/nejmoa2008470
10.1183/13993003.00172-2024
10.1183/13993003.00172-2024
10.1164/rccm.202107-1766oc
10.1164/rccm.202107-1766oc
10.1136/bmjresp-2022-001310
10.1136/bmjresp-2022-001310
10.1164/rccm.202109-2174oc
10.1164/rccm.202109-2174oc
Preclinical models support the synergistic potential of seralutinib and sotatercept in treating pulmonary arterial hypertension (PAH)
2026
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
10.1016/s2213-2600(22)00097-2 · 2022
10.1016/j.healun.2020.09.011
10.1016/j.healun.2020.09.011
10.1007/s00330-024-11209-1
10.1007/s00330-024-11209-1
10.1016/j.chest.2024.02.046
10.1016/j.chest.2024.02.046
Overlapping pulmonary hypertension phenotypes in smokers: a call to action
10.1016/s2213-2600(25)00259-0 · 2025
Ten-year survival and prognostic factors after BPA in inoperable CTEPH
2025
10.1183/13993003.01294-2024
10.1183/13993003.01294-2024
Thoracic applications of spectral CT scan
10.1016/j.chest.2023.07.4225 · 2024
A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer
10.1055/a-2145-7238 · doi-reference
Value-based assessment of implementing a pulmonary embolism response team (PERT)
10.1007/s11239-020-02188-3 · doi-reference
Do pulmonary embolism response teams for acute pulmonary embolism improve outcomes? Insights from a meta-analysis
10.1016/j.amjcard.2025.04.017 · doi-reference
Revised paradigm for acute pulmonary embolism prognostication and treatment
10.1164/rccm.202212-2234vp · doi-reference
10.1183/13993003.01647-2019
10.1183/13993003.01647-2019 · doi-reference
10.1136/bmj.l4416
10.1136/bmj.l4416 · doi-reference
10.1378/chest.13-1087
10.1378/chest.13-1087 · doi-reference
What echocardiographic findings differentiate acute pulmonary embolism and chronic pulmonary hypertension?
10.1016/j.ajem.2023.07.011 · doi-reference
Pulmonary artery imaging with 68Ga-FAPI-04 in patients with chronic thromboembolic pulmonary hypertension
10.1007/s12350-022-03069-3 · doi-reference
10.2967/jnumed.111.093344
10.2967/jnumed.111.093344 · doi-reference
Ventilation/perfusion SPECT for the diagnosis of pulmonary embolism: a systematic review
10.1111/jth.15038 · doi-reference
10.1183/13993003.02225-2022
10.1183/13993003.02225-2022 · doi-reference
10.1148/radiol.2018180603
10.1148/radiol.2018180603 · doi-reference
10.1007/s00330-023-09777-9
10.1007/s00330-023-09777-9 · doi-reference
Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): dual-energy CT experience in 31 patients
10.1007/s00330-016-4500-6 · doi-reference